Clinical Trials

Treatment with SD-101 distributed via pressure-enabled drug delivery with immune checkpoint inhibition was tolerated and resulted in the depletion of regulatory T cells (Tregs), monocytic myeloid-derived suppressor cells (M-MDSCs), and M2 macrophages in liver metastases in patients with uveal melanoma, according to data from the phase 1 PERIO-01 trial (NCT04935229) presented at the 2023 SITC Annual Meeting.

The addition of bemcentinib (BGB324) to the standard-of-care (SOC) therapies of pembrolizumab (Keytruda) or dabrafenib (Tafinlar) plus trametinib (Mekinist) was well tolerated in patients with metastatic melanoma; however, it did not lead to improvements in overall response rate (ORR), progression-free survival (PFS), or overall survival (OS) vs SOC alone, according to data from the phase 1b/2 BGBIL006 trial (NCT02872259).

Uveal melanoma is a rare type of eye cancer. Less than 2,000 people are diagnosed with the disease annually in the United States. It is treatable, however, roughly half of uveal melanoma patients will develop metastatic disease, most commonly to the liver, drastically reducing their chance for survival.

Elizabeth I. Buchbinder, MD, discusses findings from a retrospective study evaluating the resumption of nivolumab maintenance therapy in patients with advanced melanoma who discontinued treatment with the combination of nivolumab and ipilimumab due to immune-related adverse effects.